Page 21 - TD-3-3

Tumor Discovery Immune and epigenetic therapies for TNBC

41. Paroni G, Zanetti A, Barzago MM, et al. Retinoic acid 52. Takahashi M, Cortés J, Dent R, et al. Pembrolizumab plus
sensitivity of triple-negative breast cancer cells characterized chemotherapy followed by pembrolizumab in patients
by constitutive activation of the notch1 pathway: The role of with early triple-negative breast cancer: A secondary
rarβ. Cancers (Basel). 2020;12(10):3027. analysis of a randomized clinical trial. JAMA Netw Open.
doi: 10.3390/cancers12103027 2023;6(11):E2342107.
42. Lim C, Hwang D, Yazdimamaghani M, et al. High-dose doi: 10.1001/jamanetworkopen.2023.42107.
paclitaxel and its combination with CSF1R inhibitor in 53. Fattori S, Roy A Le, Houacine J, et al. CD25high effector
polymeric micelles for chemoimmunotherapy of triple- regulatory T cells hamper responses to PD-1 blockade in triple-
negative breast cancer. Nano Today. 2023;51:101884. negative breast cancer. Cancer Res. 2023;83(18):3026-3044.
doi: 10.1016/j.nantod.2023.101884 doi: 10.1158/0008-5472.CAN-23-0613
43. Connolly RM, Rudek MA, Piekarz R. Entinostat: 54. Strauss J, Heery CR, Schlom J, et al. Phase I trial of M7824
A promising treatment option for patients with advanced (MSB0011359C), a bifunctional fusion protein targeting
breast cancer. Future Oncol. 2017;13(13):1137-1148. PD-L1 and TGFβ, in advanced solid tumors. Clin Cancer
doi: 10.2217/fon-2016-0526 Res. 2018;24(6):1287-1295.
44. Fuso P, Muratore M, D’angelo T, et al. PI3K inhibitors in doi: 10.1158/1078-0432.CCR-17-2653
advanced breast cancer: The past, the present, new challenges 55. Bhola NE, Balko JM, Dugger TC, et al. TGF-β inhibition
and future perspectives. Cancers (Basel). 2022;14:2161. enhances chemotherapy action against triple-negative breast
doi: 10.3390/cancers14092161 cancer. J Clin Invest. 2013;123(3):1348-1358.
45. Cinier J, Hubert M, Besson L, et al. Recruitment and doi: 10.1172/JCI65416
expansion of Tregs cells in the tumor environment-how to 56. Hu C, Liu X, Zeng Y, Liu J, Wu F. DNA methyltransferase
target them? Cancers (Basel). 2021;13(8):1850. inhibitors combination therapy for the treatment of
doi: 10.3390/cancers13081850 solid tumors: mechanism and clinical application. Clin
Epigenetics. 2021;13:166.
46. Plitas G, Konopacki C, Wu K, et al. Regulatory T cells
exhibit distinct features in human breast cancer. Immunity. doi: 10.1186/s13148-021-01154-x
2016;45(5):1122-1134. 57. Terranova-Barberio M, Thomas S, Ali N, et al. HDAC
doi: 10.1016/j.immuni.2016.10.032 inhibition potentiates immunotherapy in triple-negative
breast cancer. Oncotarget. 2017;8(29):48223-48235.
47. Liu F, Lang R, Zhao J, et al. CD8+ cytotoxic T cell and
FOXP3+ regulatory T cell infiltration in relation to breast doi: 10.18632/oncotarget.23169
cancer survival and molecular subtypes. Breast Cancer Res 58. Zahran AM, El-Badawy O, Kamel LM, Rayan A, Rezk K,
Treat. 2011;130(2):645-655. Abdel-Rahim MH. Accumulation of regulatory T cells in
doi: 10.1007/s10549-011-1647-3 triple-negative breast cancer can boost immune disruption.
Cancer Manag Res. 2021;13:6019-6029.
48. Yeong J, Thike AA, Lim JCT, et al. Higher densities of
Foxp3+ regulatory T cells are associated with better doi: 10.2147/CMAR.S285128
prognosis in triple-negative breast cancer. Breast Cancer Res 59. Oshi M, Asaoka M, Tokumaru Y, et al. Abundance of
Treat. 2017;163(1):21-35. regulatory T cell (Treg) as a predictive biomarker for
doi: 10.1007/s10549-017-4161-4 neoadjuvant chemotherapy in triple-negative breast cancer.
Cancers (Basel). 2020;12(10):3038.
49. Letendre P, Monga V, Milhem M, Zakharia Y. Ipilimumab:
From preclinical development to future clinical perspectives doi: 10.3390/cancers12103038
in melanoma. Future Oncol. 2017;13:625-636. 60. Qin D, Zhang Y, Shu P, Lei Y, Li X, Wang Y. Targeting tumor-
doi: 10.2217/fon-2016-0385 infiltrating Tregs for improved antitumor responses. Front
Immunol. 2024;15:1325946.
50. Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D,
Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer doi: 10.3389/fimmu.2024.1325946
immunotherapy. Cancers (Basel). 2021;13:1440. 61. Qiu X, Zhao T, Luo R, Qiu R, Li Z. Tumor-associated
doi: 10.3390/cancers13061440 macrophages: Key players in triple-negative breast cancer.
Front Oncol. 2022;12:772615.
51. Howard FM, Pearson AT, Nanda R. Clinical trials of
immunotherapy in triple-negative breast cancer. Breast doi: 10.3389/fonc.2022.772615
Cancer Res Treat. 2022;195:1-15.
62. Bottai G, Raschioni C, Székely B, et al. AXL-associated
doi: 10.1007/s10549-022-06665-6 tumor inflammation as a poor prognostic signature in

Volume 3 Issue 3 (2024) 15 doi: 10.36922/td.3383